Biotech Co.*
(Country;
Symbol)

Pharma Co. (Country)

Product

Terms/Details (Date)


Alba
Therapeutics
Corp.*

Peptisyntha
(affiliate of Solvay
SA; Belgium)

Peptisyntha will lead the manufacturing process development of Alba's upcoming products

Details on the deal were not disclosed (8/20)

AltaRex
Medical Corp.
(Canada; TSE:ALT)

Dompe International SA (Switzerland)

Dompe got exclusive rights to distribute OvaRex MAb in certain areas, and rights of first refusal to other cancer antibodies

The rights and option cover Italy, Spain, Portugal, Hungary, Poland, Czech Republic, Switzerland, Austria and other Eastern European countries; they entered a memorandum of understanding on this deal in 2000 (7/6)

Caliper Life
Sciences Inc.
(CALP)

Sigma-Aldrich Corp.

Deal to develop and co-market a series of automated turnkey solutions

The products would have applications in genomics, proteomics and drug discovery (8/16)

Cangene
Corp.
(Canada;
TSE:CNJ)

Baxter Healthcare Corp.

Baxter will take over U.S. distribution of Cangene's WinRho SDF in March 2005

Baxter will replace Nabi Biopharmaceuticals as distributor; a Baxter affiliate already distributes the product in Europe (7/20)

Chiral Quest
Inc.
(OTC BB:
CQST)

DSM Pharma Chemicals (the Netherlands)

Deal to further develop applications of CQ's catalytic products and technology

DSM got a license to use the technology, for use in manufacturing intermediates in the life sciences sector (7/14)

Chiral Quest Inc. (OTC BB: CQST)

Sigma-Aldrich Corp.

Deal under which Sigma will distribute Chiral Quest ligands

The deal covers the Binaphane, C3-Tune-Phos, TangPhos and Binapine ligands; terms were not disclosed (7/13)

Codexis Inc.*

Lonza Group Ltd. (Switzerland)

Lonza will use the Codexis biocatalytic process for synthesis of a chiral pharmaceutical compound

Codexis will receive license fees and royalties, and sell biocatalysts to Lonza for use in the production process, which will involve Codexis' directed molecular evolution platform (7/27)

CombiMatrix
Group
(CBMX)

Strand Genomics Pvt. Ltd. (India)

Co-marketing deal for avadis, a data- analysis software tool for microarray gene expression

Terms on the deal covering CombiMatrix's avadis were not disclosed (7/9)

Connetics Corp. (CNCT)

Hoffmann-La Roche Inc.

Deal under which Connetics can sell Soriatane to an unnamed distributor for exportation to select international markets

Connetics will pay a royalty to Roche on Soriatane sales to the distributor; Connetics acquired rights to the oral psoriasis drug from Roche earlier this year (7/28)

Corixa Corp. (CRXA)

GlaxoSmithKline Biologicals (Belgium)

Deal through 2012 covering manufacturing and supply of Corixa's adjuvant, monophos-phoryl lipid A, or MPL

Corixa gets a multimillion-dollar up-front licensing fee and supply payments, as well as royalties on sales of any GSK vaccine containing MPL adjuvant; a provision allows Corixa to repay a $5M loan in stock rather than cash (7/26)

EntreMed Inc.
(ENMD)

Elan Drug Delivery Inc. (unit of Elan Corp. plc)

Elan will reformulate and manufacture EntreMed's Panzem in an oral liquid form

Elan will use its NanoCrystal technology in the deal, terms of which were not disclosed (7/13)

Generex
Biotechnology
Corp.
(Canada;
GNBT)

PharmaBrand SA (Ecuador)

Expanded joint venture to include Farmacid SA, an Ecuadorian manufacturer of pharmaceutical products that's a PharmaBrand affiliate

Their venture now will include a turnkey filling operation for Oralin as a first step toward global commercialization of the product; Generex gets a 25% equity interest in the entire manufacturing facility (8/26)

Inyx
Inc.
(OTC BB:IYXI)

AstraZeneca plc (UK)

Inyx will help develop a version of AstraZeneca's Pulmicort asthma spray for European markets

The three and a half year contract is valued at $6.5M per year to Inyx, which will develop a non-ozone-depleting hydrofluoralkane version of the product (6/29)

MGI Pharma
Inc.
(MOGN)

Alpharma Inc.

MGI will promote Alpharma's sustained- release morphine product, Kadia, in the U.S. for pain associated with cancer

Intitially in the three-year deal they will share profits from MGI sales; further terms were not disclosed (7/14)

Microbix
Biosystems
Inc.
(Canada;
TSE:MBX)

Undisclosed vaccine producer

Microbix's technology for enhancing virus yield

Companies entered exclusive negotiation period; Microbix gets monthly payments during the review, and $1M if it delivers a fourfold yield improvement; it then could get milestone and royalty payments (6/18)

Molecular Insight Pharmaceuticals Inc.*

MDS Nordion (unit of MDS Inc.; Canada)

MDS will manufacture BMIPP, Molecular Insight's molecular imaging product that's in Phase II trials for detecting ischemia

The product is labeled with MDS' iodine-123; terms of the deal were not disclosed (6/16)

MWG Biotech AG (Germany;FSE:NWUG)

Unnamed company

Global supply contract for oligonucleotides

MWG expects annual revenue of €1M from the deal with the pharmaceutical company; details were not disclosed (7/29)

NeoPharm
Inc.
(NEOP)

Nippon Genetics Co. Ltd. (Japan)

Nonexclusive worldwide distribution and marketing agreement for Neopharm's NeoPhectin and NeoPhectin-AT

Nippon Genetics will market and promote the transfection reagents to its customers worldwide; terms were not disclosed (8/5)

NPE Systems Inc.*

Beckman Coulter Inc.

Exclusive licensing and development agreement on NPE's flow-based cellular analysis systems

Beckman Coulter will integrate NPE's Quanta family of products into its Cell Lab suite of cellular analysis solutions; terms were not disclosed (8/11)

Qiagen NV
(the Netherlands;
QGENF)

Novartis Pharma
AG (Switzerland)

Qiagen will be the global supplier for products and services related to nucleic acids

Terms of the deal were not disclosed (8/2)

Qiagen NV (the Netherlands; QGENF)

AstraZeneca plc (UK)

Qiagen will supply siRNA molecules to AstraZeneca

Qiagen will be the preferred supplier for siRNA products used in gene silencing; terms were not disclosed (6/30)

Transkaryotic Therapies Inc. (TKTX)

Lonza Biologics plc (UK)

Lonza will manufacture TKT's Dynepo, an erythropoietin product

Terms were not disclosed; TKT looks to have the product on the market in Europe in late 2005 or early 2006 (8/3)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments